Rapport Therapeutics, Inc. RAPP
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 57.15% | -- | |||
| Gross Profit | -304.33% | -- | |||
| SG&A Expenses | -18.32% | 39.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.52% | 14.82% | |||
| Operating Income | -151.11% | 37.12% | |||
| Income Before Tax | -185.11% | 41.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -185.11% | 41.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -185.11% | 41.19% | |||
| EBIT | -151.11% | 37.12% | |||
| EBITDA | -152.60% | 37.28% | |||
| EPS Basic | -183.68% | 41.51% | |||
| Normalized Basic EPS | -183.75% | 41.52% | |||
| EPS Diluted | -183.68% | 41.51% | |||
| Normalized Diluted EPS | -183.75% | 41.52% | |||
| Average Basic Shares Outstanding | 0.50% | 0.55% | |||
| Average Diluted Shares Outstanding | 0.50% | 0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||